News about the treatment of rheumatic diseases Middle East

Recent developments in the treatment of rheumatic diseases

Logo of the Sixth International Conference of the Saudi Rheumatology Society

– In light of what was discussed at the Sixth International Conference of the Saudi Society of Rheumatic Disease, many developments are in this regard:
– First: advanced drugs. Says Dr. Dr. Ibrahim Al-Hamoud There is a wide range of biological drugs and new drugs taken orally. These drugs have completely changed the nature of rheumatic diseases and do not cause many complications, but rarely present with joint malformations. Biological drugs are already a revolution in rheumatism and their types and groups are many and different, all available in the Kingdom. Biologic drugs differ in terms of work mechanism and in terms of impact on the patient. Since each patient of a certain nature, the doctor is the one who decides who determines and selects the appropriate treatment for the case.
The most recent of these drugs is Secukinumab, a fully human monoclonal antibody, selectively associated with IL-17A and inhibiting its effects. It is considered to be the least effective side effect in the treatment of Ankylosing Spondylitis (AS) and Psoriatic Arthritis. Arthritis (RP) is part of the arthritic disease of the spine. (J Am Acad Dermatol 2017 Jan)
– Second: the possibility of stopping treatment. Dr. Adibah Al-Harz, consulting rheumatologist and chairman of the Kuwait Rheumatism Association, spoke at the 6th Saudi Rheumatology Society Conference, confirming that rheumatic diseases were chronic diseases.
Now, there are justifications for stopping treatment: that the disease has been treated from the beginning with proper and correct treatment, and that the disease is under control and has not returned for a long time, and that the burden of the disease is not serious for the patient and that all the tests are correct. To this end, some tasks have been implemented as follows:
Many studies have shown that rheumatoid and rheumatoid patients in particular can stop treatment when the disease is under control for 6 months or a year and that 50% of these patients can control the disease and lead a normal life, but 50% disease can be reactivated after a while, but the treatment can control the disease again, allowing patients to live naturally.
A study conducted by the State of Kuwait with rheumatologists revealed that 75% of patients preferred to reduce rheumatism and that they stopped treatment after a certain time, which is very important because the patient is exposed to side effects. . It does not matter what kind of treatment he's taking. This method provides the patient with side effects that can affect his health, while reducing the financial burden on him and the Ministry of Health and the state.
– The need to meet the doctor and the patient to discuss the pros and cons of the subject and present all the means and options available, then agree on a plan and share a decision with the consent of the patient.